Phase 2 Spinal Muscular Atrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older (or the legal adult age in your country) at the time of signing the consent form.
- You must have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed by a tissue or cell sample.
- Your prostate cancer must have spread to other parts of your body (metastatic disease).
- Your testosterone levels must be very low (50 ng/dL or below), which typically means you are receiving hormone-suppressing treatment.
- Your cancer must show signs of getting worse, shown by either rising PSA blood test results (at least 3 rising readings, each at least 1 week apart), cancer growth visible on scans, or 2 or more new bone spots found on a bone scan.
- You must be generally well enough to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
- Your blood counts and organ function (such as liver and kidneys) must be at acceptable levels.
- Depending on which part of the trial you join, you must have received at least 1 (and in some parts, no more than 2) prior hormone-blocking cancer treatments called ARPIs.
- Depending on which part of the trial you join, you may need to have received at least 1 prior chemotherapy treatment containing a taxane drug, or in one specific group, you must NOT have had any prior taxane chemotherapy.
Who may not be able to join:
- You have a type of prostate cancer other than adenocarcinoma, such as small cell or neuroendocrine prostate cancer.
- You have cancer that has spread to the brain or is pressing on the spinal cord.
- You have significant heart rhythm problems or an abnormal heart tracing (ECG) (confirm with trial site).
- You have serious heart or blood vessel conditions, such as heart failure, uncontrolled high blood pressure, recent heart attack, heart muscle disease, valve problems, irregular heartbeat (atrial fibrillation), or a history of stroke.
- You have an active digestive condition or other issue that could affect how the study drug is absorbed or processed by your body.
- You have a known tendency to bleed easily, such as an active stomach ulcer, a stroke involving bleeding within the past 6 months, or a serious eye condition related to diabetes.
- You have previously been treated with a specific type of cancer drug called an AR-PROTAC (confirm with trial site if unsure).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only); Number of participants with Adverse Events and Serious Adverse Events; Number of participants with Adverse Events leading to discontinuation of study intervention; Clinically significant changes from baseline in vital signs.; Clinically significant changes from baseline in physical examination.; Clinically significant changes from baseline in ECOG PS.; Clinically significant changes from baseline in ECGs.; Clinically significant changes from baseline in laboratory parameters.; Proportion of part...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.